Search company, investor...
Elucid company logo

Elucid

elucid.com

Founded Year

2009

Stage

Series B | Alive

Total Raised

$35.37M

Last Raised

$27M | 7 mos ago

About Elucid

Elucid is a medical technology company leveraging machine intelligence to improve the accuracy, experience, and cost-effectiveness of vascular diagnostic imaging. Its product, ElucidVivo, is an FDA-cleared & CE-marked, histology-validated, non-invasive image analysis software for evaluating CTAs to provide multi-dimensional visualization, structural measurements, and plaque composition to inform risk of an event (heart attack or stroke) and personalized treatment selection. Elucid was founded in 2009 and is based in Boston, Massachusetts.

Headquarters Location

2 Park Plaza Suite 305

Boston, Massachusetts, 02116,

United States

617-329-9487

Elucid's Product Videos

Product Demo

ESPs containing Elucid

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTH ➡MARKET STRENGTH ➡LEADERHIGHFLIEROUTPERFORMERCHALLENGER
Healthcare / Healthcare Providers Tech

Companies in this market range from ones that detect signs of stroke in advance of onset to those that offer gamified rehab options as part of the recovery from a stroke. With this disease, time is of the essence for diagnosis and successful treatment.

Elucid named as Highflier among 8 other companies, including Brainomix, Orpyx Medical Technologies, and Intradys.

Compete with Elucid?

Ensure that your company and products are accurately represented on our platform.

Elucid's Products & Differentiators

    ElucidVivo

    Software that analyzes the type and amount of plaque in the arteries.

Research containing Elucid

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Elucid in 1 CB Insights research brief, most recently on Jun 25, 2021.

Expert Collections containing Elucid

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Elucid is included in 6 Expert Collections, including Health Monitoring & Diagnostics.

H

Health Monitoring & Diagnostics

2,908 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

D

Digital Health

13,405 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

M

Medical Devices

3,286 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

D

Digital Health 150

150 items

The winners of the third annual CB Insights Digital Health 150.

H

Health IT

363 items

Elucid Patents

Elucid has filed 27 patents.

The 3 most popular patent topics include:

  • Medical imaging
  • Magnetic resonance imaging
  • Vascular diseases
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/4/2020

11/22/2022

Obesity, Connective tissue, Vascular diseases, Medical imaging, Angiology

Grant

Application Date

8/4/2020

Grant Date

11/22/2022

Title

Related Topics

Obesity, Connective tissue, Vascular diseases, Medical imaging, Angiology

Status

Grant

Latest Elucid News

Elucid Appoints Scott Burger as Chief Commercial Officer

Jan 26, 2023

Cardiovascular industry veteran will help propel Elucid’s next generation AI-powered software to the forefront of disease risk prediction and management January 26, 2023 07:00 AM Eastern Standard Time BOSTON--( BUSINESS WIRE )-- Elucid, Inc. , a leading medical technology company providing physicians with AI-powered imaging analysis software to characterize cardiovascular disease, today announced the addition of Scott Burger as chief commercial officer. His appointment comes as Elucid expands the commercial footprint of its PlaqueIQ technology, the only FDA-cleared plaque analysis software to identify and match CT images to patient tissue samples, simulating what a pathologist would see under a microscope. “We welcome Scott to our senior leadership team at this important time of growth for the company. His vast range of leadership experiences in the medical device and services space is exactly what we are looking for to take us to the next level as we increase our commercial footprint,” said Blake Richards, chief executive officer, Elucid. “Scott’s knowledge and track record of success will be vital for Elucid as we launch several next generation plaque and FFRCT products in the coming months.” Scott brings more than 15 years of leadership experience and will lead sales, marketing, market access and customer success. He joins Elucid from CorVista Health, a non-invasive cardiac diagnostics company that combines advanced disciplines of mathematics, physics and machine-learning to reshape existing care pathways. Prior to his tenure at CorVista, Scott was commercial vice president at HeartFlow, and previously held leadership roles at Johnson & Johnson, superDimension, Bard and ConvaTec. “Being at the forefront of what’s next in cardiovascular care is my passion, and I am thrilled to join Elucid at this exciting time of growth,” said Burger. “Elucid’s next generation FFRCT and plaque analysis has the potential to change how cardiovascular disease is managed and I look forward to working with the talented team to accelerate the adoption of Elucid’s groundbreaking technology.” About Elucid Elucid is a Boston-based medical technology company dedicated to bringing precision patient care, as currently practiced in oncology, to cardiology. Its AI-powered imaging analysis software, PlaqueIQ, is designed to deeply understand the biology of cardiovascular disease. The only FDA-cleared analysis software that objectively quantifies plaque morphology based on actual biology (validated against tens of thousands of tissue samples), PlaqueIQ equips physicians with critical information for assessing the risk of plaque rupture in arteries that can lead to heart attack and stroke. The Elucid Plaque Analysis software is available for commercial use in the U.S. and South Korea. For more information, visit elucid.com . Contacts

Elucid Frequently Asked Questions (FAQ)

  • When was Elucid founded?

    Elucid was founded in 2009.

  • Where is Elucid's headquarters?

    Elucid's headquarters is located at 2 Park Plaza, Boston.

  • What is Elucid's latest funding round?

    Elucid's latest funding round is Series B.

  • How much did Elucid raise?

    Elucid raised a total of $35.37M.

  • Who are the investors of Elucid?

    Investors of Elucid include Bluestone Venture Partners, IAG Capital Partners, MedTex Ventures, BioVision, Bold Brain Ventures and 7 more.

  • Who are Elucid's competitors?

    Competitors of Elucid include MyndTec, Methinks AI, Time is Brain, Cleerly, Forest Devices, MicroTransponder, Intradys, DoYCan, CVAid Medical, iCardin and 18 more.

  • What products does Elucid offer?

    Elucid's products include ElucidVivo and 1 more.

Compare Elucid to Competitors

BURL Concepts Logo
BURL Concepts

BURL Concepts is developing a portable, battery-powered ultrasound device designed for the non-invasive, transcranial diagnosis of strokes 'In The Field'. Using disposable ultrasound transducers it works in combination with ultrasound microbubbles. Acoustic Response Analysis (ARA) has been developed as a technology to adapt automatically the acoustic output power to the individual skull 'finger print' of a patient. Based on acoustic pattern recognition ARA allows to differentiate between underlying hemorrhagic or ischemic events as a cause for the stroke. The BURL Device carries wireless technology for real-time data transfer to a dedicated location.

D
DoYCan

Do Y Can focus on the development and application of SaaS service platform based on telerehabilitation integration for stroke patients' full course rehabilitation management. The company through the application of sports rehabilitation digital medical treatment, the APP is used to realize a three-level network rehabilitation medical service system consisting of "tertiary hospitals + community health service stations + families". The company was founded in 2017 and is based in Guangzhou, China.

Semacare Logo
Semacare

Semacare is an artificial intelligence platform that improves health outcomes by allowing for earlier diagnosis of serious heart conditions. Semacare's cloud platform and portable clinical-grade ECG and Pulse Oximeter provides data for early heart failure and stroke prevention diagnosis and monitoring Q-T prolongation (the key indicator of a heart condition that causes sudden death).

Forest Devices Logo
Forest Devices

Forest Devices getting stroke patients to the right hospitals faster by creating the technology with diagnosis in the pre-hospital environment. The company has created AlphaStroke, which is a bench top prototype that will be able to detect ischemic and hemorrhagic stroke in the pre-hospital environment. The company was founded in 2015 and is based in Pittsburgh, Pennsylvania.

H
Heuron

Heuron develops an AI diagnostic assistant platform for brain nerve disorders, such as dementia, stroke, and Parkinson's disease. It is based in Incheon, South Korea.

i
iCardin

iCardin is a stroke management and comprehensive neurology care provider.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.